Nora Schweitzer1, Tim Weber1, Martha M Kirstein1, Mareike Fischer1,2, Anna-Maria Kratzel1, Tanja Reineke-Plaaß3, Frank Lehner4, Michael P Manns1, Arndt Vogel5. 1. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hanover, Germany. 2. Department of Cardiology, Angiology and Intensive Care, Klinikum Hildesheim, Senator-Braun-Allee 33, 31135, Hildesheim, Germany. 3. Department of Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hanover, Germany. 4. Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hanover, Germany. 5. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hanover, Germany. vogel.arndt@mh-hannover.de.
Abstract
PURPOSE: The purpose of this study was to identify prognostic factors of patients with intrahepatic cholangiocarcinoma (ICC) treated with resection and to investigate the effect of adjuvant chemotherapy (CT). METHODS: Patients with ICC diagnosed between 2000 and 2015 treated at Hannover Medical School were included. Clinicopathologic characteristics were analyzed in univariate and multivariate analysis. In a matched pair survival analysis, patients with or without adjuvant CT were matched by these prognostic factors. RESULTS: Two hundred and ten patients were included. Median survival was 28.7 months, 1-, 3-, and 5-year survival rates were 72.8%, 29.6%, and 14.1%, respectively. In multivariate analysis, lymph node involvement (p = 0.006, HR 1.84), larger tumor size (p = 0.013, HR 1.79), vascular invasion (p = 0.038, HR 1.70), and prolongation of prothrombin time (p < 0.001, HR 4.20) were significantly related to poor survival. Thirty-nine patients received adjuvant CT of which 60% had lymph node involvement. Each 25 patients with and without adjuvant CT were matched to the identified prognostic factors. The median survival of patients with adjuvant CT was 33.5 months, compared to 18 months in the control group (p = 0.002). The 1-, 3-, and 5-year survival rates were 96, 36, and 12%, compared to 60, 4, and 0% in non-treated patients. CONCLUSIONS: We identified several prognostic factors for patients with ICC treated with resection. Our data support the use of adjuvant CT in patients with ICC. The results of prospective randomized controlled studies will clarify the role of adjuvant CT in the future.
PURPOSE: The purpose of this study was to identify prognostic factors of patients with intrahepatic cholangiocarcinoma (ICC) treated with resection and to investigate the effect of adjuvant chemotherapy (CT). METHODS:Patients with ICC diagnosed between 2000 and 2015 treated at Hannover Medical School were included. Clinicopathologic characteristics were analyzed in univariate and multivariate analysis. In a matched pair survival analysis, patients with or without adjuvant CT were matched by these prognostic factors. RESULTS: Two hundred and ten patients were included. Median survival was 28.7 months, 1-, 3-, and 5-year survival rates were 72.8%, 29.6%, and 14.1%, respectively. In multivariate analysis, lymph node involvement (p = 0.006, HR 1.84), larger tumor size (p = 0.013, HR 1.79), vascular invasion (p = 0.038, HR 1.70), and prolongation of prothrombin time (p < 0.001, HR 4.20) were significantly related to poor survival. Thirty-nine patients received adjuvant CT of which 60% had lymph node involvement. Each 25 patients with and without adjuvant CT were matched to the identified prognostic factors. The median survival of patients with adjuvant CT was 33.5 months, compared to 18 months in the control group (p = 0.002). The 1-, 3-, and 5-year survival rates were 96, 36, and 12%, compared to 60, 4, and 0% in non-treated patients. CONCLUSIONS: We identified several prognostic factors for patients with ICC treated with resection. Our data support the use of adjuvant CT in patients with ICC. The results of prospective randomized controlled studies will clarify the role of adjuvant CT in the future.
Authors: Richard S Hoehn; Koffi Wima; Audrey E Ertel; Alexandra Meier; Syed A Ahmad; Shimul A Shah; Daniel E Abbott Journal: Ann Surg Oncol Date: 2015-05-15 Impact factor: 5.344
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas Journal: J Hepatol Date: 2002-12 Impact factor: 25.083
Authors: Alexander R Siebenhüner; Heike Seifert; Helga Bachmann; Burkhardt Seifert; Thomas Winder; Jonas Feilchenfeldt; Stefan Breitenstein; Pierre-Alain Clavien; Roger Stupp; Alexander Knuth; Bernhard Pestalozzi; Panagiotis Samaras Journal: BMC Cancer Date: 2018-01-11 Impact factor: 4.430
Authors: Ka Wing Ma; Tan To Cheung; Brian Leung; Brian Wong Hoi She; Kenneth Siu Ho Chok; Albert Chi Yan Chan; Wing Chiu Dai; Chung Mau Lo Journal: Medicine (Baltimore) Date: 2019-02 Impact factor: 1.817